Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 769-774

  Cho, Kang Su ^a   Joung, Jae Young ^a   Seo, Ho Kyung ^a   Cho, In Chang ^a   Chung, Han Soo ^a   Chung, Jinsoo ^a   Lee, Kang Hyun ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Nephroureterectomy; Renal function; Urothelial carcinoma

Indexed keywords

CISPLATIN; CREATININE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROURETERECTOMY; PRIORITY JOURNAL; SIDE EFFECT; SOLITARY KIDNEY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CREATININE; DATABASES, FACTUAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PALLIATIVE CARE; TREATMENT OUTCOME; URETERAL NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 79954449045     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1349-2     Document Type: Article

References (26)

1. MC Hall S Womack AI Sagalowsky T Carmody MD Erickstad CG Roehrborn 1998 Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients Urology 52 594 601 9763077 10.1016/S0090-4295(98)00295-7 1:STN:280:DyaK1cvjsVSnsw%3D%3D (Pubitemid 28440164)
2. C Langner G Hutterer T Chromecki I Winkelmayer P Rehak R Zigeuner 2006 pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract Mod Pathol 19 272 279 16424895 10.1038/modpathol.3800529 (Pubitemid 43117612)
3. V Margulis SF Shariat SF Matin AM Kamat R Zigeuner E Kikuchi, et al. 2009 Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration Cancer 115 1224 1233 19156917 10.1002/cncr.24135
4. NJ Hellenthal SF Shariat V Margulis PI Karakiewicz M Roscigno C Bolenz, et al. 2009 Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration J Urol 182 900 906 19616245 10.1016/j.juro.2009.05.011
5. JE Uhm HY Lim WS Kim HY Choi HM Lee BB Park, et al. 2007 Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract Neoplasia 9 18 22 17325740 10.1593/neo.06661 1:CAS:528:DC%2BD2sXhvFCht7k%3D (Pubitemid 46203931)
6. H von der Maase SW Hansen JT Roberts L Dogliotti T Oliver MJ Moore, et al. 2000 Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 3068 3077 11001674
7. PJ Loehrer Sr LH Einhorn PJ Elson ED Crawford P Kuebler I Tannock, et al. 1992 A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1066 1073 1607913
8. ED Poggio X Wang DM Weinstein N Issa VW Dennis WE Braun, et al. 2006 Assessing glomerular filtration rate by estimation equations in kidney transplant recipients Am J Transplant 6 100 108 16433763 10.1111/j.1600-6143. 2005.01140.x 1:STN:280:DC%2BD28%2FksV2qtQ%3D%3D (Pubitemid 43382207)
9. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0. http://ctep.info.nih.gov/reporting/ctc.html. http://ctep.info.nih.gov/reporting/ctc.html
10. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
11. WC Huang AS Levey AM Serio M Snyder AJ Vickers GV Raj, et al. 2006 Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study Lancet Oncol 7 735 740 16945768 10.1016/S1470-2045(06)70803-8 (Pubitemid 44283660)
12. SM Lucas JM Stern M Adibi IS Zeltser JA Cadeddu GV Raj 2008 Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques J Urol 179 75 79 17997440 10.1016/j.juro.2007.08.156 (discussion 79-80) (Pubitemid 350216747)
13. A Dash MD Galsky AJ Vickers AM Serio TM Koppie G Dalbagni, et al. 2006 Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 506 513 16773629 10.1002/cncr.22031 1:CAS:528:DC%2BD28Xot1aksLs%3D (Pubitemid 44107210)
14. GV Raj A Iasonos H Herr SM Donat 2006 Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer J Clin Oncol 24 3095 3100 16809735 10.1200/JCO.2005.04.3091 1:CAS:528:DC%2BD28XnslKhs7k%3D (Pubitemid 46638946)
15. PE Kintzel RT Dorr 1995 Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function Cancer Treat Rev 21 33 64 7859226 10.1016/0305-7372(95)90010-1 1:STN:280:DyaK2M7mtlSgsA%3D%3D
16. I Arany RL Safirstein 2003 Cisplatin nephrotoxicity Semin Nephrol 23 460 464 13680535 10.1016/S0270-9295(03)00089-5 1:CAS:528:DC%2BD3sXoslyrtbs%3D (Pubitemid 37176691)
17. JA Garcia R Dreicer 2006 Systemic chemotherapy for advanced bladder cancer: update and controversies J Clin Oncol 24 5545 5551 17158540 10.1200/JCO.2006.08.0564 1:CAS:528:DC%2BD2sXmvVSqsw%3D%3D (Pubitemid 46631335)
18. R Petrioli B Frediani A Manganelli G Barbanti B De Capua A De Lauretis, et al. 1996 Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study Cancer 77 344 351 8625244 10.1002/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1 1:CAS:528:DyaK28Xht1ajtbs%3D (Pubitemid 26023354)
19. J Bellmunt A Ribas N Eres J Albanell C Almanza B Bermejo, et al. 1997 Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 80 1966 1972 9366300 10.1002/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W 1:CAS:528:DyaK2sXns1ygtb4%3D (Pubitemid 27479792)
20. L Dogliotti G Carteni S Siena O Bertetto A Martoni A Bono, et al. 2007 Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial Eur Urol 52 134 141 17207911 10.1016/j.eururo. 2006.12.029 1:CAS:528:DC%2BD2sXotFyltrg%3D (Pubitemid 46803003)
21. S Culine 2007 Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Eur Urol 52 9 10 17239527 10.1016/j.eururo.2007.01.017 (Pubitemid 46803011)
22. S Herget-Rosenthal A Bokenkamp W Hofmann 2007 How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 40 153 161 17234172 10.1016/j.clinbiochem.2006.10.014 1:CAS:528:DC%2BD2sXntlOiug%3D%3D (Pubitemid 46108706)
23. M Sambataro K Thomaseth G Pacini C Robaudo A Carraro M Bruseghin, et al. 1996 Plasma clearance rate of 51Cr-EDTA provides a precise and convenient technique for measurement of glomerular filtration rate in diabetic humans J Am Soc Nephrol 7 118 127 8808118 1:STN:280:DyaK28vgtlynsg%3D%3D
24. S Quasthoff HP Hartung 2002 Chemotherapy-induced peripheral neuropathy J Neurol 249 9 17 11954874 10.1007/PL00007853 1:CAS:528:DC%2BD38XisVKkt7k%3D (Pubitemid 34119018)
25. LP Rybak 2007 Mechanisms of cisplatin ototoxicity and progress in otoprotection Curr Opin Otolaryngol Head Neck Surg 15 364 369 17823555 10.1097/MOO.0b013e3282eee452 (Pubitemid 47373985)
26. KS Han JY Joung TS Kim IG Jeong HK Seo J Chung, et al. 2008 Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy Br J Cancer 98 86 90 18087289 10.1038/sj.bjc.6604113 1:CAS:528:DC%2BD1cXisF2rug%3D%3D